Publication & Citation Trends
Publications
0 total
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors OA
Cited by 20
Semantic Scholar
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial OA
Cited by 61
Semantic Scholar
Abstract PR018: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors
Cited by 9
Semantic Scholar
163 Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression OA
Cited by 3
Semantic Scholar
959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial OA
Cited by 25
Semantic Scholar
293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101)
Cited by 3
Semantic Scholar
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma OA
Cited by 139
Semantic Scholar
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. OA
Cited by 20
Semantic Scholar
Research Topics
CAR-T cell therapy research
(20)
Tuberculosis Research and Epidemiology
(8)
Immunotherapy and Immune Responses
(7)
Immune Cell Function and Interaction
(6)
Mycobacterium research and diagnosis
(6)
Affiliations
Oklahoma State University
Houston Methodist
Universität Hamburg
Baylor College of Medicine
Northeastern State University